Cochrane · systematic review · CD004767
Interventions for cutaneous molluscum contagiosum
van der Wouden, JC, van der Sande, R, Kruithof, EJ, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 71.4%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Imiquimod versus vehicle for cutaneous molluscum contagiosum
Population: molluscum contagiosum
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Short‐term clinical cure (up to 3 months after start of treatment) (completely cleared short term) Imiquimod vs vehicle | RR 1.33 [0.92, 1.93] | 4 studies · 850 participants | Moderate Downgraded: risk of bias, imprecision |
Medium‐term clinical cure (after 3 months and up to 6 months after start of treatment) (completely cleared medium term) Imiquimod vs vehicle | RR 0.88 [0.67, 1.14] | 2 studies · 702 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Long‐term clinical cure (beyond 6 months after start of treatment) (completely cleared long term) Imiquimod vs vehicle | RR 0.97 [0.79, 1.17] | 2 studies · 702 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Short‐term clinical improvement (up to 3 months after start of treatment) Imiquimod vs vehicle | RR 1.14 [0.89, 1.47] | 4 studies · 850 participants | High |
Any adverse effect Imiquimod vs vehicle | RR 0.97 [0.88, 1.07] | 3 studies · 827 participants | High |
Application site reactions Imiquimod vs vehicle | RR 1.41 [1.13, 1.77] | 3 studies · 827 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Severe application site reactions Imiquimod vs vehicle | RR 4.33 [1.16, 16.19] | 3 studies · 827 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |